Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,404.00
Bid: 12,424.00
Ask: 12,426.00
Change: 58.00 (0.47%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,470.00
Low: 12,322.00
Prev. Close: 12,346.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

The high growth companies that could re-rate in a recession

Wed, 28th Jun 2023 10:55

STOXX 600 up 0.6%, techs among big gainers

*

British SME software maker Sage hits 23-year high

*

Europe stocks head for solid gains in June

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

THE HIGH GROWTH COMPANIES THAT COULD RE-RATE IN A RECESSION (0947 GMT)

The re-rating of high quality and high growth names could be on the horizon in Europe, according to BofA quant strategist Paulina Strzelinska.

While BofA prefers value over growth during the recession phase - given an increased focus on dividend returns - the expected decline in the bond yield nevertheless means high quality names could be positively impacted.

And a lot of those high quality names are also high growth, writes Strzelinska.

BofA provides a list of such names. The list spans companies that are part of the STOXX 600 and have a market cap of at least 500 million euros, and score above 60 on BofA's quality, growth and 'recession' rankings.

The likes of Danish healthcare company Novo Nordisk , French luxury giant Hermes and UK defence company BAE Systems are at the top of the list.

They are followed by France's L'Oreal, Dutch IT company Wolters Kluwer and Italy's Ferrari.

(Lucy Raitano)

TECH TAKES CHARGE IN EUROPE AS NVIDIA RETREATS (0832 GMT)

The STOXX 600 is off to a perky start today, up around 0.6% as it heads for a 0.8% gain this month. Tech stocks, led by Dutch chipmaker ASML and Germany's SAP are among the top weighted gainers on the broader index.

2023's trillion-dollar tech darling Nvidia is down nearly 4% in the premarket after a report in the Wall Street Journal on Tuesday that the U.S. is considering new restrictions on exports of AI chips to China. Nvidia, along with rivals Micron and AMD, are caught in the crossfire between China and Joe Biden's administration right now. Might this mean an edge for their competitors on the other side of the pond?

Amsterdam's AEX is outperforming the broader market, with a gain of nearly 0.7%, as is Frankfurt's DAX, with a gain of 0.8%, thanks to SAP. London's FTSE is around the middle of the pack, with a 0.4% rise on the day, thanks to Astrazeneca, up 0.6% and Sage Group, up 4.1% at a 23-year high after JPMorgan upgraded the software maker, which supplies small and medium-sized companies.

Here's your opening snapshot:

(Amanda Cooper)

EUROPEAN FUTURES RISE (0644 GMT)

European shares were set to open higher on Wednesday taking strength from a positive close on Wall Street following surprisingly upbeat data that showed the U.S. economy is weathering rising rates better than initially thought.

EuroSTOXX50 and FTSE futures were up 0.5% and 0.3% respectively, while in Asia, shares stalled amid lingering concerns over rising interest rates.

Policy makers from Fed Chair Jerome Powell to ECB's Christine Lagarde will have their chance to speak again later in the day at a central banking forum in Portugal.

With little corporate newsflow out there, chipmakers are likely to grab the attention after a WSJ report said Washington was considering new curbs on exports of artificial intelligence chips to China. China's CSI AI index was down over 3% and so Nvidia shares fell by the same magnitude in Frankfurt.

Still on AI, the CEO of business software maker SAP said he saw huge growth potential in generative AI technology.

In M&A, chemicals group Arkema announced a proposed acquisition of a majority stake in South Korean company PI Advanced Materials for 728 million euros ($796.50 million).

BEIJING LEAVES MARKET GUESSING ON YUAN (0558 GMT)

The People's Bank of China seems to like being enigmatic, throwing the market a curve ball as it fixed the yuan weaker against the dollar than many expected. Dealers had thought the firmer fix on Tuesday meant Beijing was signalling it wanted the yuan's fall to slow, or even stop. Now, not so much.

The result has been a drop in the offshore yuan back toward Monday's trough, while the market waits for some clarity on Beijing's intentions.

Sentiment was also not helped by a Wall Street Journal report that Washington is considering new restrictions on exports of artificial intelligence chips to China, which shaved 3% off Nvidia's share price.

The rest of Asia would certainly appreciate a steadier yuan since its fall puts pressure on their currencies to depreciate, to keep their exports competitive with China. Malaysia is set to be the latest to intervene to support its currency, and Japan sounds closer to pulling the trigger every day.

"We are closely watching currency moves with a strong sense of urgency," Japan's top currency diplomat warned, which is about as close as the Ministry of Finance gets to an outright ultimatum.

The last time the MOF intervened, in 2022, they sold a thumping $43 billion of dollars in just two days, so the threat is not to be sniffed at. It was enough to stall the dollar at 144.0 yen, while the euro eased off a 15-year high on the yen.

Still, the market is clearly betting the yen will keep falling unless, and until, the Bank of Japan backs away from its yield curve policy. Bank of Japan chief Ueda speaks later today at the European Central Bank's Sintra jamboree, and will have to justify his super-easy policy while every other central bank on the panel is busy tightening.

It will also be interesting to see if ECB chief Lagarde expands on the idea that firms should stop padding their margins by raising prices - a variation of the argument that this is a profit-price spiral rather than a wage-price spiral.

Once this would have been scorned as a radical view of the far-left fringe, but it's increasingly gaining mainstream acceptance. An OECD study earlier this month argued that profits were a major driver of inflation, especially in the energy and agriculture sectors.

It's tempting to think that, if wages are not the culprit, then central banks might not have to push unemployment up as much as in the past to curb inflation. Yet, Lagarde's conclusion was that policy would need to be tighter for longer so as to hurt demand enough that firms restrained their hunger for profits. That's still a recipe for higher unemployment.

On the bright side, Australian data out Wednesday did show CPI inflation slowing by more than expected to a 13-month low, and that followed a sharp slowdown in Canadian inflation. So maybe there's hope yet.

Key developments that could influence markets on Wednesday:

- ECB President Christine Lagarde, Fed's Jerome Powell, BOJ Governor Kazuo Ueda and Bank of England Governor Andrew Bailey take part in ECB panel in Sintra, Portugal, 1230 GMT

- U.S. data on wholesale and retail inventories, advance goods trade balance

(Wayne Cole)

More News
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.